iCAD, Inc. (ICAD)
Stock Price Chart
Key Info
| Market Cap | 223.28M |
| Revenue (ttm) | 29.36M |
| Net Income (ttm) | -20.51M |
| Shares Out | 22.90M |
| EPS (ttm) | -1.01 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | Oct 19, 2020 |
| Last Price | $9.75 |
| Previous Close | $9.41 |
| Change ($) | 0.34 |
| Change (%) | 3.61% |
| Day's Open | 9.51 |
| Day's Range | 9.50 - 9.90 |
| Day's Volume | 127,379 |
| 52-Week Range | 5.91 - 15.31 |
More Stats
| Market Cap | 223.28M |
| Enterprise Value | 208.30M |
| Earnings Date (est) | Oct 28, 2020 |
| Ex-Dividend Date | n/a |
| Shares Outstanding | 22.90M |
| Float | 20.96M |
| EPS (basic) | -1.02 |
| EPS (diluted) | -1.01 |
| FCF / Share | -0.39 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
| Payout Ratio | n/a |
| Shares Short | 1.10M |
| Short Ratio | 4.49 |
| Short % of Float | 5.23% |
| Beta | 1.35 |
| PE Ratio | n/a |
| Forward PE | n/a |
| P/FCF Ratio | n/a |
| PS Ratio | 7.61 |
| PB Ratio | 8.13 |
| Revenue | 29.36M |
| Operating Income | -10.11M |
| Net Income | -20.51M |
| Free Cash Flow | -8.62M |
| Net Cash | 14.98M |
| Net Cash / Share | 0.65 |
| Gross Margin | 83.88% |
| Operating Margin | -34.44% |
| Profit Margin | -69.90% |
| FCF Margin | -29.35% |
| ROA | -14.27% |
| ROE | -109.73% |
| ROIC | -133.90% |
Analyst Summary
Analyst Consensus: Buy
Financial Performance
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 31.34 | 25.62 | 28.10 | 26.34 | 41.55 | 43.92 | 33.07 | 28.28 | 28.65 | 24.58 |
| Revenue Growth | 22.32% | -8.83% | 6.7% | -36.62% | -5.4% | 32.83% | 16.95% | -1.32% | 16.59% | - |
| Gross Profit | 24.23 | 19.43 | 18.18 | 18.52 | 29.35 | 31.23 | 23.09 | 20.03 | 20.03 | 19.69 |
| Operating Income | -6.40 | -8.13 | -14.17 | -9.97 | -30.08 | 0.82 | -1.78 | -5.41 | -37.12 | -6.54 |
| Net Income | -13.55 | -9.02 | -14.26 | -10.10 | -32.45 | -1.01 | -7.61 | -9.37 | -37.59 | -6.22 |
| Shares Outstanding | 18.38 | 16.69 | 16.34 | 15.93 | 15.69 | 14.10 | 10.84 | 10.80 | 10.91 | 9.17 |
| Earnings Per Share | -0.74 | -0.54 | -0.87 | -0.63 | -2.07 | -0.07 | -0.70 | -0.87 | -3.45 | -0.68 |
| Operating Cash Flow | -7.11 | -3.87 | -7.34 | -5.48 | -1.90 | 3.20 | -1.43 | -4.20 | -10.14 | 0.21 |
| Capital Expenditures | -0.30 | -0.30 | -0.39 | -0.34 | -0.93 | -1.21 | -0.54 | -0.67 | -0.26 | -0.32 |
| Free Cash Flow | -7.40 | -4.17 | -7.73 | -5.82 | -2.83 | 1.99 | -1.97 | -4.87 | -10.41 | -0.12 |
| Cash & Equivalents | 15.31 | 12.19 | 9.39 | 8.59 | 15.28 | 32.22 | 11.88 | 13.95 | 4.58 | 16.94 |
| Total Debt | 22.49 | 13.10 | 5.98 | 0.09 | 1.06 | 11.67 | 15.88 | 14.85 | - | - |
| Net Cash / Debt | -7.18 | -0.92 | 3.41 | 8.50 | 14.23 | 20.55 | -4.00 | -0.90 | 4.58 | 16.94 |
| Assets | 41.75 | 31.74 | 32.13 | 38.65 | 48.64 | 93.77 | 58.92 | 59.99 | 51.76 | 95.59 |
| Liabilities | 36.68 | 24.84 | 17.86 | 13.61 | 15.89 | 30.99 | 37.54 | 32.33 | 15.71 | 22.38 |
| Book Value | 5.07 | 6.90 | 14.28 | 25.04 | 32.75 | 62.78 | 21.38 | 27.67 | 36.06 | 73.21 |
Company Profile
Company Details
| Full Name | iCAD, Inc. |
| Country | United States |
| Employees | 135 |
| CEO | Michael S. Klein |
Stock Information
| Ticker Symbol | ICAD |
| Stock Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Health Information Services |
| Unique Identifier | NASDAQ: ICAD |
| IPO Date | December 3, 1986 |
Description
iCAD provides image analysis, workflow solutions, and radiation therapy for the early identification and treatment of cancer in the United States and internationally. It operates through two segments, Cancer Detection and Cancer Therapy. The company provides electronic brachytherapy (eBX) products, including Axxent eBx systems for the treatment of early stage breast cancer, endometrial cancer, cervical cancer, and skin cancer, as well as for treating other cancers or conditions where radiation therapy is indicated comprising intraoperative radiation therapy. It also offers digital mammography computer-aided detection (CAD) products, which include PowerLook Mammo Detection, which detects and identifies suspicious masses and micro-calcifications; and PowerLook Platform, a server residing on a customer's network that receives patient studies from the imaging modality, performs analysis, and sends results to picture archiving and communication system and/or review workstations. In addition, the company offers magnetic resonance imaging products to detect breast and prostate cancer; breast tomosynthesis systems; and advanced image analysis and workflow solutions in computed tomography (CT) colonography, including VeraLook that supports the detection of colonic polyps in conjunction with CT colonography. It serves healthcare centers through direct sales organizations, as well as through various original equipment manufacturer partners, distributors, and resellers. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was founded in 1984 and is headquartered in Nashua, New Hampshire.